Hisashi Noma

ORCID: 0000-0002-2520-9949 · 4 papers in corpus · active 2017-2023

Study types

  • article 3
  • dataset 1

Condition tags

  • endometriosis 4
  • dysmenorrhea 4
  • endometrioma 2
  • adenomyosis 2
  • mesh:D017699 1
  • mesh:D004715 1
  • mesh:D004412 1
article 2023
Evaluation of the Characteristics of Ovarian Endometriomas in Patients with Endometriosis: Efficacy of a Low-Dose Estrogen/Progestogen Combination
Gynecologic and obstetric investigation ·doi:10.1159/000534666

OBJECTIVES: Approximately 17-44% of women diagnosed with endometriosis have ovarian endometriomas (cysts). Although ovarian endometriomas may adversely affect quality of life and work performance, the associations among patient characterist…

dataset 2023
Supplementary Material for: Evaluation of the characteristics of ovarian endometrioma in patients with endometriosis: efficacy of a low-dose estrogen/progestogen combination
·doi:10.6084/m9.figshare.24547369

Objectives: Approximately 17–44% of women diagnosed with endometriosis have ovarian endometriomas (cysts). Although ovarian endometriomas may adversely affect quality of life and work performance, no reports have been published on the relat…

article 2017
SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial
·doi:10.33160/yam.2017.12.003

Background SR-16234 is a selective estrogen receptor modulator (SERM) structurally different from approved SERM and has been reported to have estrogen receptor (ER) α antagonistic activity and strong affinity with a weak partial agonistic a…

article 2017
SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial.
Yonago acta medica ·doi:10.24563/yam.2017.12.003

Background: SR-16234 is a selective estrogen receptor modulator (SERM) structurally different from approved SERM and has been reported to have estrogen receptor (ER) α antagonistic activity and strong affinity with a weak partial agonistic …